# A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease

> **NCT07647133** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 249 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** SAL0140 Tablets
- **DRUG:** SAL0140 Tablets
- **DRUG:** SAL0140 placebo

## Key facts

- **NCT ID:** NCT07647133
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-10-08
- **Final completion:** 2027-12-31
- **Target enrollment:** 249 (ESTIMATED)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647133, "A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*